Markets:

Overview

News

Currencies

International

Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

15.88 -0.38 (-2.31%)

Streaming Delayed Price Updated: 2:47 PM EDT, May 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2

...

13 14 15 16 17 18 19 20 Next >

The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug ↗

September 30, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (...

Via Benzinga

Takeda In-Licenses Hunter Syndrome Candidate ↗

September 30, 2021

Takeda Pharmaceutical Company Limited (NYSE: TAK) and JCR Pharmaceuticals Co Ltd have announced an exclusive collaboration and license agreement to...

Via Benzinga

Takeda to Commercialize Next-Generation Hunter Syndrome Therapy Through Collaboration with JCR Pharmaceuticals

September 30, 2021

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Guilty Of Supply Contract Breach With AbbVie For Prostate Cancer Drug ↗

September 24, 2021

In a spat between Takeda Pharmaceutical Co Ltd (NYSE: TAK) and AbbVie Inc (NYSE: ABBV) for Lupron (leuprorelin), a Delaware judge has issued a ruling in...

Via Benzinga

Takeda Selects Four New Partners for Annual Global Corporate Social Responsibility (CSR) Program to Help Strengthen Health Systems in Low- and Middle-Income Countries

September 22, 2021

From Takeda Pharmaceutical Company Limited

Via Business Wire

9 Health Care Stocks Showing Unusual Options Activity In Today's Session ↗

September 21, 2021

This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges...

Via Benzinga

Mirum, Takeda Ink Maralixibat Licensing Pact In Japan ↗

September 21, 2021

Mirum Pharmaceuticals Inc (NASDAQ: MIRM) and Takeda Pharmaceutical Company Limited (NYSE: TAK) have entered into an exclusive licensing agreement for...

Via Benzinga

Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan

September 21, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight ↗

September 19, 2021

Biotech stocks declined for the week ending Sept. 17, extending the losses from the previous week. European Society for Medical Oncology presentations, vaccine news, clinical...

Via Benzinga

The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study ↗

September 16, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Alcon Inc. (NYSE: ALC)...

Via Benzinga

Takeda's Exkivity Scores FDA Nod As First Oral Therapy For Lung Cancer With EGFR Exon20 Insertion ↗

September 16, 2021

The FDA has approved Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Exkivity (mobocertinib) for non-small cell lung cancer (NSCLC) settings. The approval comes for...

Via Benzinga

Takeda’s EXKIVITY™ (mobocertinib) Approved by U.S. FDA as the First Oral Therapy Specifically Designed for Patients with EGFR Exon20 Insertion+ NSCLC

September 15, 2021

From Takeda Pharmaceutical Company Limited

Via Business Wire

Pressure Day ↗

September 13, 2021

Today a recovery came to markets with a particular impact on uranium shares.

Via Talk Markets

ADHD Drug Developer Cingulate Plans NASDAQ Debut ↗

September 10, 2021

Cingulate Inc filed for an IPO, penciling in a modest $58 million raise, and expects to list on NASDAQ under CING ticker. Cingulate has a Phase 3-ready attention...

Via Benzinga

Topics Initial Public Offering

Why Novavax Stock Is Slipping Again Today ↗

September 10, 2021

A reported delay in India's EUA for Novavax's COVID-19 vaccine appears to still be weighing on the stock.

Via The Motley Fool

Why Novavax Stock Surged Today ↗

September 07, 2021

The biotech's coronavirus-related revenue could be about to soar.

Via The Motley Fool

NVAX Stock: The Big Reason Why Novavax Shares Are Gaining Today ↗

September 07, 2021

A Japanese pharma giant has partnered with Novavax to supply millions of vaccines. NVAX stock is reacting accordingly.

Via InvestorPlace

Novavax Shares Surge On Vaccine Supply Deal With Japan ↗

September 07, 2021

Novavax, Inc. shares were trading higher Tuesday following the signing of a coronavirus vaccine supply deal.

Via Talk Markets

Novavax Shares Surge On Vaccine Supply Deal With Japan ↗

September 07, 2021

Novavax, Inc. (NASDAQ: NVAX) shares were trading higher Tuesday following the signing of a coronavirus vaccine supply deal. What Happened: Japanese pharma giant Takeda...

Via Benzinga

Mu - The Newest Worry ↗

September 03, 2021

Today London and New York fell on the huge drop in new employment levels in August.

Via Talk Markets

Takeda's Breakthrough Blood Cancer Drug Flunks In Phase 3 Study ↗

September 02, 2021

Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced topline data from the Phase 3 PANTHER study evaluating pevonedistat in blood cancer indications. The trial did...

Via Benzinga

The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab ↗

September 02, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1) AbbVie Inc. (NASDAQ: ABBV...

Via Benzinga

Takeda Provides Update on Phase 3 PANTHER (Pevonedistat-3001) Trial

September 01, 2021

From Takeda Pharmaceutical Company Limited

Via Business Wire

Moderna Reviews Contamination In Vaccine Lot Distributed In Japan ↗

September 01, 2021

Moderna, Inc. (NASDAQ: MRNA) found itself in a controversy after Japan suspended the use of about 2.6 million doses of the company's COVID-19 vaccine following reports of...

Via Benzinga

UK's NICE Rejects Johnson & Johnson's Darzalex Regime For Newly Diagnosed Myeloma ↗

August 30, 2021

New guidance from the National Institute for Health and Care Excellence (NICE) has rejected a combination regimen based on Johnson & Johnson's (NYSE: JNJ)...

Via Benzinga

Moderna Withdraws Additional COVID-19 Shots In Japan: What You Need To Know ↗

August 30, 2021

After receiving reports on more contaminated vials and two deaths, Japan has suspended another million doses of Moderna Inc's (NASDAQ: MRNA) COVID-19...

Via Benzinga

Topics Death

Suspected Metallic Particles Behind Moderna's Japan COVID-19 Jab Contamination: Reuters ↗

August 27, 2021

Metallic particle is believed to be a contaminant found in a batch of Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccines delivered to Japan, Japanese public broadcaster...

Via Benzinga

Exelixis - Takeda's Cabometyx Scores Approval In Japan For Kidney Cancer ↗

August 26, 2021

Exelixis Inc's (NASDAQ: EXEL) collaborating partner Takeda Pharmaceutical Co Ltd (NYSE: TAK) and Ono Pharmaceutical Co Ltd have received...

Via Benzinga

Moderna Withdraws 1.6M COVID-19 Vaccine Doses In Japan Over Contamination Concerns ↗

August 26, 2021

More than a million doses of Moderna Inc’s (NASDAQ: MRNA) coronavirus vaccine have been taken out of circulation in Japan after reports of contamination emerged, Nikkei Asia...

Via Benzinga

BioLife Plasma Services Opens First All-Electric Plasma Donation Center

August 18, 2021

From Takeda Pharmaceutical Company Limited

Via Business Wire

< Previous 1 2

...

13 14 15 16 17 18 19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.